Destiny Pharma PLC | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Destiny Pharma PLC

BRIEF

published on 08/20/2024 at 12:57, 3 months ago

Destiny Pharma to Present XF-73 Nasal Gel Data at ESCMID Conference

Clinical Data Antibiotic Resistance XF-73 Nasal Gel ESCMID Conference Cardiac Surgery
PRESS RELEASE

published on 08/20/2024 at 12:52, 3 months ago

Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
Destiny Pharma to deliver presentation on XF-73 Nasal Gel at ESCMID conference highlighting rapid reduction in S. aureus nasal burden and lower need for post-operative antibiotics

Destiny Pharma XF-73 Nasal Gel ESCMID Conference S. Aureus Post-operative Antibiotics
BRIEF

published on 08/14/2024 at 12:25, 3 months 6 days ago

Destiny Pharma Initiates Research to Explore XF Drug Potential for CF

Biotechnology Cystic Fibrosis MRSA Drug Research XF-73
PRESS RELEASE

published on 08/14/2024 at 12:20, 3 months 6 days ago

Destiny Pharma initiates research to explore XF drug potential for CF
Destiny Pharma initiates research to explore XF drug potential for CF. Study focusing on XF-73 to treat MRSA infection in people with cystic fibrosis. Details on the project and potential benefits

Clinical Study Destiny Pharma XF Drug CF Research MRSA Infection
BRIEF

published on 08/13/2024 at 10:41, 3 months 8 days ago

Destiny Pharma plc Shares Now Trading on JP Jenkins

Biotechnology JP Jenkins Share Trading Destiny Pharma Innovative Medicines
PRESS RELEASE

published on 08/13/2024 at 10:36, 3 months 8 days ago

Destiny Pharma plc shares now trading on JP Jenkins
Destiny Pharma plc shares now trading on JP Jenkins. Clinical stage biotechnology company focused on preventing & curing infections. Shares admitted to JP Jenkins trading platform

Shares Biotechnology JP Jenkins Trading Platform Destiny Pharma Plc

Accesswire

Published on 11/21/2024 at 10:03, 44 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 47 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 47 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 12 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 22 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 17 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 42 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 45 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 47 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 47 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 27 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 2 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 2 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE